Delcath Systems' Innovative Liver Cancer Treatments Showcase at Upcoming MedTech Conference

Delcath Systems Advances Interventional Oncology with Innovative Liver Cancer Treatments

Delcath Systems, Inc., a pioneering interventional oncology company based in Queensbury, NY, focuses on addressing the critical challenge of treating liver cancers, both primary and metastatic. The company is set to participate in the upcoming BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, scheduled for February 11-12, 2025, in Snowbird, Utah. This conference provides an essential platform for Delcath to showcase its advancements in liver cancer therapies to a broad audience of industry professionals and investors.

Central to Delcath's innovative approach are its proprietary products, including the HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System. These systems allow for the targeted delivery of high-dose chemotherapy directly to the liver, significantly improving treatment efficacy while minimizing systemic exposure and associated side effects. The HEPZATO KIT combines the chemotherapeutic agent melphalan with the Hepatic Delivery System (HDS), which isolates hepatic venous blood from systemic circulation during the infusion and washout phases. This method enables a localized administration of melphalan, potentially leading to substantial tumor responses while reducing the risk of hepatotoxicity.

The HEPZATO KIT is currently approved by the FDA for use in adult patients in the United States who have metastatic uveal melanoma (mUM) and unresectable hepatic metastases, assuming that no more than 50% of the liver is affected and any extrahepatic disease is suitable for resection or radiation. Meanwhile, in Europe, the HDS is classified as a Class III medical device under the CHEMOSAT name, where it has demonstrated effectiveness in major medical centers for various liver cancer treatments. As Delcath Systems continues to expand its reach in the interventional oncology field, these innovations hold promise for improving patient outcomes in the challenging landscape of liver cancer therapies.

In addition to its participation in the BTIG conference, Delcath Systems emphasizes the importance of understanding the potential risks associated with its products. The HEPZATO KIT includes a BOXED WARNING in its Prescribing Information, highlighting critical safety considerations for healthcare providers and patients alike. This commitment to transparency ensures that users are fully informed about the treatment's benefits and risks, reinforcing Delcath's dedication to patient safety in its innovative cancer therapies.

As Delcath Systems prepares to engage with the medical community at the upcoming conference, the company's advancements in interventional oncology signify a significant step forward in the fight against liver cancer, paving the way for enhanced therapeutic options for patients in need.